{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:23:14Z","timestamp":1791987794491,"version":"4.4.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Tapentadol is the first of a new class of analgesics, having synergistic \u00b5-opioid receptor agonist and noradrenaline reuptake inhibitory actions. It has been widely researched in many areas of pain, often in noninferiority studies against potent opioids. This review describes all randomized and recent nonrandomized studies of tapentadol in adults with cancer pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Tapentadol has been shown to be at least as effective as morphine and oxycodone in five randomized (two of which were multicenter and double-blind) and a range of nonrandomized trials, although caution is needed when interpreting these results. It is effective in both opioid-naive patients and those already taking opioids. By having a lower \u00b5-opioid receptor binding affinity, it has fewer opioid-related toxicities such as constipation and nausea. A recent randomized trial comparing tapentadol to tapentadol plus duloxetine in patients with chemotherapy-induced peripheral neuropathy shows similar improvement in both groups in a range of pain relieving and quality of life measures, with similar adverse effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Tapentadol has been shown in a range of studies to be an effective analgesic and thus should be considered as an alternative to morphine and oxycodone, especially when opioid toxicities are an issue.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/spc.0000000000000641","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T10:00:09Z","timestamp":1678874409000},"page":"90-97","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Tapentadol for the management of cancer pain in adults: an update"],"prefix":"10.1097","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5272-3057","authenticated-orcid":false,"given":"Jason W.","family":"Boland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"R1-20250525","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s40265-021-01515-z","article-title":"Tapentadol versus tramadol: a narrative and comparative review of their pharmacological, efficacy and safety profiles in adult patients","volume":"81","author":"Roulet","year":"2021","journal-title":"Drugs"},{"key":"R2-20250525","doi-asserted-by":"crossref","first-page":"912361","DOI":"10.3389\/fphar.2022.912361","article-title":"Trends of dispensed opioids in Catalonia, Spain, 2007-19: a population-based Cohort study of over 5 million individuals","volume":"13","author":"Xie","year":"2022","journal-title":"Front Pharmacol"},{"key":"R3-20250525","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/pharmaceutics14020237","article-title":"Trends in the prescription of strong opioids for chronic non-cancer pain in primary care in Catalonia: Opicat-Padris-Project","volume":"14","author":"Perello-Bratescu","year":"2022","journal-title":"Pharmaceutics"},{"key":"R4-20250525","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2147\/JPR.S190160","article-title":"Pharmacological rationale for tapentadol therapy: a review of new evidence","volume":"12","author":"Romualdi","year":"2019","journal-title":"J Pain Res"},{"key":"R5-20250525","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2147\/JPR.S191543","article-title":"Tapentadol in the management of cancer pain: current evidence and future perspectives","volume":"12","author":"Kress","year":"2019","journal-title":"J Pain Res"},{"key":"R6-20250525","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40263-022-00924-2","article-title":"Current and future therapeutic options in pain management: multi-mechanistic opioids involving both MOR and NOP receptor activation","volume":"36","author":"Coluzzi","year":"2022","journal-title":"CNS Drugs"},{"key":"R7-20250525","first-page":"e26000","article-title":"Multimechanistic single-entity combinations for chronic pain control: a narrative review","volume":"14","author":"Pergolizzi","year":"2022","journal-title":"Cureus"},{"key":"R8-20250525","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/03007995.2020.1748876","article-title":"Modulation of sensitization processes in the management of pain and the importance of descending pathways: a role for tapentadol?","volume":"36","author":"Caraci","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"R9-20250525","first-page":"1672","article-title":"From acute to chronic pain: tapentadol in the progressive stages of this disease entity","volume":"21","author":"Coluzzi","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R10-20250525","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s12325-018-0778-x","article-title":"Does \u2018strong analgesic\u2019 equal \u2018strong opioid\u2019? Tapentadol and the concept of \u2018micro-Load\u2019","volume":"35","author":"Raffa","year":"2018","journal-title":"Adv Ther"},{"key":"R11-20250525","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-018-1007-2","article-title":"Tapentadol prolonged release: a review in pain management","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"R13-20250525","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1248\/bpb.b20-00084","article-title":"Pharmacokinetic analysis, analgesic effects, and adverse effects of tapentadol in cancer patients with pain","volume":"43","author":"Homma","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"R14-20250525","doi-asserted-by":"crossref","first-page":"e00921","DOI":"10.1002\/prp2.921","article-title":"Tapentadol shows lower intrinsic efficacy at micro receptor than morphine and oxycodone","volume":"10","author":"Manandhar","year":"2022","journal-title":"Pharmacol Res Perspect"},{"key":"R15-20250525","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1124\/jpet.110.175042","article-title":"Synergistic interaction between the two mechanisms of action of tapentadol in analgesia","volume":"337","author":"Schroder","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R16-20250525","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s40618-018-0964-3","article-title":"Testosterone deficiency in non-cancer opioid-treated patients","volume":"41","author":"Coluzzi","year":"2018","journal-title":"J Endocrinol Invest"},{"key":"R17-20250525","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"van den Beuken-van Everdingen","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"R18-20250525","first-page":"CD011460","article-title":"Oral tapentadol for cancer pain","volume":"2015","author":"Wiffen","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R19-20250525","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/papr.12556","article-title":"Tapentadol for cancer pain management: a narrative review","volume":"17","author":"Carmona-Bayonas","year":"2017","journal-title":"Pain Pract"},{"key":"R20-20250525","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.3390\/cancers14164002","article-title":"Comparative efficacy of tapentadol versus tapentadol plus duloxetine in patients with chemotherapy-induced peripheral neuropathy (CIPN): a randomized non-inferiority clinical trial","volume":"14","author":"Sansone","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R21-20250525","doi-asserted-by":"crossref","first-page":"329","DOI":"10.36076\/ppj.2014\/17\/329","article-title":"Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain","volume":"17","author":"Kress","year":"2014","journal-title":"Pain Physician"},{"key":"R22-20250525","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40261-014-0204-3","article-title":"Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release","volume":"34","author":"Imanaka","year":"2014","journal-title":"Clin Drug Investig"},{"key":"R23-20250525","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1185\/03007995.2013.831816","article-title":"Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain","volume":"29","author":"Imanaka","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"R25-20250525","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/ejp.875","article-title":"Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain","volume":"20","author":"Kress","year":"2016","journal-title":"Eur J Pain"},{"key":"R26-20250525","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.1007\/s00520-022-06992-w","article-title":"A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naive or opioid-resistant patients","volume":"30","author":"Jung","year":"2022","journal-title":"Support Care Cancer"},{"key":"R27-20250525","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s10072-017-3035-1","article-title":"Tapentadol in neuropathic pain cancer patients: a prospective open label study","volume":"38","author":"Galie","year":"2017","journal-title":"Neurol Sci"},{"key":"R28-20250525","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1248\/bpb.b21-00212","article-title":"Tapentadol in cancer patients with neuropathic pain: a comparison of methadone, oxycodone, fentanyl, and hydromorphone","volume":"44","author":"Takemura","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"R29-20250525","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s00540-020-02821-8","article-title":"Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naive and opioid-tolerant patients: a retrospective study","volume":"34","author":"Sazuka","year":"2020","journal-title":"J Anesth"},{"key":"R30-20250525","first-page":"1635","article-title":"Tapentadol safety and patient characteristics associated with treatment discontinuation in cancer therapy: a retrospective multicentre study in Japan","volume":"10","author":"Iwaki","year":"2021","journal-title":"Pain Ther"},{"key":"R31-20250525","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5055\/jom.2022.0719","article-title":"Clinical role and safety of tapentadol in patients with cancer: a single-center experience","volume":"18","author":"Kubo","year":"2022","journal-title":"J Opioid Manag"},{"key":"R32-20250525","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11916-020-00934-z","article-title":"Tapentadol, buprenorphine, and levorphanol for the treatment of neuropathic pain: a systematic review","volume":"25","author":"Erosa","year":"2021","journal-title":"Curr Pain Headache Rep"},{"key":"R33-20250525","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/03007995.2020.1832977","article-title":"Safety of tapentadol compared with other opioids in chronic pain treatment: network meta-analysis of randomized controlled and withdrawal trials","volume":"37","author":"Freynhagen","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"R34-20250525","first-page":"E75","article-title":"Long-term effectiveness and tolerability of pain treatment with tapentadol prolonged release","volume":"24","author":"Mateos","year":"2021","journal-title":"Pain Physician"},{"key":"R35-20250525","doi-asserted-by":"crossref","first-page":"10126","DOI":"10.1038\/s41598-022-13085-5","article-title":"Oxycodone\/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study","volume":"12","author":"Barrachina","year":"2022","journal-title":"Sci Rep"},{"key":"R36-20250525","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.3390\/biomedicines10102468","article-title":"Sex differences in oxycodone\/naloxone vs. tapentadol in chronic non-cancer pain: an observational real-world study","volume":"10","author":"Barrachina","year":"2022","journal-title":"Biomedicines"},{"key":"R37-20250525","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2217\/pmt-2021-0058","article-title":"Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry","volume":"12","author":"Uberall","year":"2022","journal-title":"Pain Manag"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T18:01:01Z","timestamp":1748196061000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SPC.0000000000000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000641","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,15]]}}}